A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma.
Prince HM, Mileshkin L, Roberts A, Ganju V, Underhill C, Catalano J, Bell R, Seymour JF, Westerman D, Simmons PJ, Lillie K, Milner AD, Iulio JD, Zeldis JB, Ramsay R.
Prince HM, et al.
Clin Cancer Res. 2005 Aug 1;11(15):5504-14. doi: 10.1158/1078-0432.CCR-05-0213.
Clin Cancer Res. 2005.
PMID: 16061867
Clinical Trial.